Join Barbara Craven, Ph.D., RD, LD
Rescheduled, due to Presidential Debate
For October 27 at 9 PM EST
in the Cushing's Chat Room
Barbara Craven, Ph.D., RD, LD is a licensed dietitian in Washington, DC. She currently has a practice treating patients with HIV/AIDS and teaching general nutrition. For many years she has had an interest in holistic nutrition and often uses natural therapies in her practice.
She received her Ph.D. in Food Science from Texas A&M University in 1980 and her RD in 1981. The first years of her practice, she taught at the University level, then went into private practice counseling weight loss and athletic nutrition. Several years ago she became interested in HIV nutrition and now dedicates her skills to helping the under served manage this devastating disease through diet and natural therapies. She is currently helping write an Evidenced Based Guide for Medical Nutrition Therapy in HIV/AIDS, is writing a cookbook for HIV/AIDS nutrition, is on the Ryon White Working Committee in Senator Ted Kennedy's Office, is Chair of the DC Area Nutrition Alliance and has been invited to speak on the latest developments in HIV nutrition at the National Ryon White Review Meeting this year in Washington, DC.
Barbara's link to us is that she has had Cushing's. Like many, hers was intermittent and symptoms accumulated over many years before she was diagnosed. In November of 2003 she underwent transphenoidal surgery and her entire pituitary was removed. Many of the symptoms you have experienced or are experiencing, she has also. Many of us met Barbara at the UVA Pituitary Days Conference in April, 2004.
Barbara will answer our questions about natural therapies and diet that helps alleviate symptoms and manage weight in Cushing's disease.
Join Barbara Craven, Ph.D., RD, LD
To be Rescheduled, due to Presidential Debate
in the Cushing's Chat Room
This will be a protocol chat:
PROTOCOL INSTRUCTIONS FOR GUEST CHATS
- Once the guest is introduced, random chatting is not permitted.
- If you have a question for our guest, type only
a question mark - ? - to screen
- Your name will be placed in a queue and you will
be called on in turn.
- Please restrict yourself to one question
at a time as others are waiting to ask theirs.
A message from CUSH Treasurer, Cathy Gifford:
It's not too
The conference will be held at Vanderbilt University in
Nashville, TN. On Friday, October 22, 2004. We will also have an open forum
meeting for all attendees that will already be in Nashville on Thursday,
October 21, 2004. To assure availability, we have already made reservations
for those who pre-registered for the General Jackson mid-day lunch cruise on
Saturday, October 23, 2004. However, anyone interested inthe cruise can call
615-889-1000 to make your own reservations. (Be sure to tell them that you
would like to be a part of the CUSH group for the mid-day lunch cruise on
To register for the
Cushing's Understanding Support & Help
We are looking forward to a great conference! We have some
dynamic speakers lined up, including doctors who are Cushing's experts. Ms.
Sharmyn McGraw will be leading a workshop for us. Ms McGraw is a cured
Cushing's patient and leader ofthe UCLA support group. She was featured in
the March issue of Woman's day magazine and recently on the Montel show
speaking out about Cushing's.
If you would like to learn more about Cushing's and meet other
Cushing's patients, you don't want to miss this conference! However,
registration will be open for a few more days only, as we have let the caterer
know an exact count of attendees. (lunch will be provided on Friday, October
This is the link to registration form
It's always a most rewarding experience to meet other
Cushing's patients and we hope to meet you in Nashville!
Cushing's Understanding Support & Help Officers:
Sue Koziol, President
Leslie Dingman, Vice President
Lynne Clemens, Secretary
Cathy Gifford, Treasurer
Mary O'Connor, Internet Communications
Uniting together we can make a difference...
Please note that registration will only be open for a few more
days and will end without further notice. You can email any CUSH officer or
CUSHOrg@aol.com for any assistance that you may need.
Thursday and Friday, October 21 and 22, 2004
Saturday, October 23, 2004, Optional General Jackson Riverboat Cruise
2004 Annual CUSH Convention
Join us in Nashville for this exciting event at the
Due to unforeseen circumstance, Dr. Lewis Blevins is not going to be able to speak at our Conference on October 22, 2004. However, he is providing us with 2 video lectures specifically for our conference. His topics will be:
So....You Have Cushing's....What's Next? and Evaluation & Management of Cushing's Disease when Surgery Has Failed...
We regret that Dr. Blevins can't be with us for the conference. However, we are most confident that our remaining speakers, will excel and we will have a great conference as anticipated.
You still have time to register so get your registration form in and lets all look forward to having a great time in Nashville. It's always a rewarding experience to meet other Cushing's Patients.
Dr. Scott C Isaacs will also be among the speakers. Dr. Isaacs' topic
will be "Coping With Cushing's Through Diet and Lifestyle".
More info here »
Register for the Conference here »
Nashville Mariott @ Vanderbilt University
Rate: $99.00 per night plus appropriate taxes
Call for Reservations: 1-615-321-1300
Room Reference is: Cushing's Disease Conference
Please Note: There is a limited number of rooms with two beds so if you
plan to share your room, please reserve early. There is a $17.00 fee for parking. Carpooling is
For more information on the Marriott and the area check the following:
The Marriott at Vanderbilt
Thursday October 21, 2004
9:00 AM: CUSH Officers Meeting, Crescent Room @ Marriott
11:00 AM - 5:00 PM: Open Forum Cushing's Patient Meeting,
Crescent Room @ Marriott
**Usually when we get together we try to come to a decision about where
we all can dine together.
Friday October 22, 2004
8:30 AM - 5:00 PM: CUSH Conference at
Vanderbilt Ingram Cancer Center
Preston Research Building
8th Floor Conference Room
Saturday October 23, 2004
Dr. Lewis S. Blevins (on video)
Dr. Scott D. Isaacs
Dr. Jessica S. Devin
*TBA possible guest speaker*
Conference Includes Luncheon
Please remember this is a limited seating facility. The interest in
this conference has been overwhelming. Please send fees early. Spouses
are also invited to attend.
$50.00 Fee per person to attend which must be paid by September 1, 2004.
Acknowledgement will be sent to you when fee received. You will
receive your name badge at the door.
Please remit to:
c/o Sue Ann Koziol
911 Evanston Drive
Jackson, MI 49202
Register for the Conference here »
Optional General Jackson Riverboat Cruise
Reservations and payments must be made in advance as the seating is limited.
PDES Patient Symposium
October 9th 2004
Rochester Hills, Michigan, USA
Treatment for Growth Hormone Disorders
Social Security Disability
The Effects of Chronic Illness
Guest Speaker: Abdul K. Al-Kassab, M.D., Ph.D
Assistant Clinical Professor at Wayne State University
Feature topic: Treatment for growth hormone disorders
Acromegaly and Growth Hormone Deficiency
Topic: Social security disability:
Guest speaker: Brenda Anderson, representative for DSI,
Disability Services, Inc.
- Do you qualify for benefits?
- How to apply
- How to communicate with your physician about your health
Topic: The effects of chronic illness
Guest speaker: Bruce Hillenburg, Ph.D
How to communicate with friends and family
How to cope with long-term illness
Best Western ConCorde Inn of Rochester Hills
1919 Star Batt Drive
Rochester Hills, Michigan, United States, 48309
You may book hotel accommodations at
Map and directions are available on the Best Western ConCorde Inn website.
Very Important! RSVP as soon as possible. Continental
breakfast will be served at 9:30 a.m. Seating is limited.
To reserve seating, please call and leave a voice mail at (810) 227-2715 or
Please include your name, phone, and the number of people
that will be attending.
| |Office of Research on Women's Health
Symposium on Family Hormonal Health
Pituitary tumors are not rare and occur in nearly 20% of adults, worldwide. Although clinically significant, many of these tumors go undiagnosed for years. The abnormal hormone production caused by these tumors has severe and debilitating effects on growth, reproductive and sexual function, and neuroimmune function. Therefore, the purpose of this symposium is to increase awareness and scientific understanding of the all-encompassing nature of pituitary disorders in order to increase earlier diagnosis, disseminate knowledge of state of the art treatments, and pique interest in novel scientific study of the pathophysiology of these disorders and their many ramifications.
MEETING LOCATION & TIME
The Symposium will be held from 8:30 a.m. - 6:00 p.m. on Friday, October 29, 2004. The Symposium will take place in the Lipsett auditorium of the NIH Clinical Center, on the NIH Campus in Bethesda, Maryland. For driving directions and information on getting to the meeting using METRO, please visit the travel page.
Participants attending the conference should be able to:
1. Describe the structure of the pituitary gland and its central importance in normal functioning and disease.
2. Improve diagnostic skills for earlier detection of disease across the lifespan in men and women.
3. Discuss current treatment options for pituitary tumors.
4. Recognize the neuroendocrine effects resulting from pituitary tumors on
the patient’s psychological state and psychosocial interactions and recommend appropriate intervention.
5. Develop a novel testable hypothesis to further continued scientific investigation in the understanding of pituitary disorders.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and the Pituitary Network Association.
The NIH/FAES is accredited by the ACME to provide continuing medical education for physicians
7:30 - 8:30 Registration & Continental Breakfast (sponsored by PNA)
8:30 - 9:15
8:30 - 8:40 Introduction & Welcome
Vivian W. Pinn, M.D.
Associate Director for Research on Women's Health, NIH
Director, Office of Research on Women's Health
8:40 - 9:00 Family Hormonal Health: the Broader Picture
Yvonne Maddox, Ph.D.
National Institute of Child Health and Human Development
|9:00 - 9:15 Hormonal Disease is no Apparent Impediment to Good Health|
Captain Mohamed K. Shakir, M.D., F.A.C.P., F.R.C.P.
Director, Department of Endocrinology
National Naval Medical Center
Professor of Medicine
Uniformed Services University of the Health Sciences
9:20 - 1:00
|9:20 - 9:30 Session chair: Ian McCutcheon, M.D.|
Professor of Neuosurgery
University of Texas
M.D. Anderson Cancer Center
|9:30 - 10:05 The Pituitary Gland in Health and Disease|
Sylvia Asa , M.D., Ph.D.
Professor, Department of Laboratory Medicine and Pathobiology
University of Toronto
University Health Network and Toronto Medical Laboratories
|10:05 - 10:35 Impact of Hormonal Disorders in Childhood|
George P. Chrousos, M.D.
Chief, Pediatric and Reproductive Endocrinology Branch
National Institute of Child Health and Human Development
|11:00 - 11:30 The Transition Years: Neither Child nor Adult |
Alan Rogol , M.D., Ph.D.
Professor of Pediatrics
University of Virginia
|11:30-12:00 The Endocrinology of the Stress Response and Its Relevance to Depression, Anxiety, and Other States|
Phil Gold, M.D.
Chief, Clinical Neuroendocrinology Branch
National Institute of Mental Health
|12:00 -1:00 Three Personal Perspectives on Living with Hormonal Disorders|
Sharmyn McGraw, Bram Levy and Robert Knutzen
|1:00 - 2:00 Lunch|
2:00 - 5:30
|2:00 - 2:10 Session chair: Edward Oldfield, M.D.|
Chief, Surgical Neurology Branch,
National Institute of Neurological Diseases and Stroke
|2:10 - 2:40 The Young Male: What are his Options and Choices?|
Marc R. Blackman, M.D
National Center for Complimentary and Alternative Medicine
|2:40 - 3:10 A Young Woman's Hormonal World|
James Segars, M.D.
National Institute of Child Health and Human Development
|3:10 - 3:40 Hormonal Needs and Disorders in the Mature Female|
Janet A. Schlecte, M.D.
University of Iowa
|3:40 - 4:00 Break|
|4:00 -4:30 Surgical Treatment of Pituitary Disorders|
Edward Laws, M.D., Ph.D.
Professor of Neurosurgery & Medicine
University of Virginia
|4:30 - 5:00 Difficult Pituitary Problems: Options and Solution|
Ian McCutcheon, M.D.
Professor of Neurosurgery
University of Texas M.D. Anderson Cancer Center
5:00 - 5:45
|Moderator: Shereen Ezzat, M.D.|
Professor of Medicine and Oncology
Head, Endocine Oncology
University of Toronto
What do we Know, Where do we Go from Here and What is the Future Role of Research?
Drs. McCutcheon, Asa, Chrousos, Rogol, Laws, Oldfield and Schlechte
5:45 - 6:00
CLOSING REMARKS, ADJOURNMENT
For your convenience, a block of sleeping rooms has been reserved at the:
5151 Pooks Hill Road
Bethesda, MD 20814
In order to receive the government rate of $150 per night (plus tax) single/double, you must call Marriott reservations directly at 800.228.9290 and reference the group name "NIH-ORWH Joint Hormonal Symposium". You must make your hotel reservation by October 7, 2004 in order to receive the group rate. Rates and availability after that date will be cannot be guaranteed.
Shuttle service departs from the Bethesda Marriott for the NIH campus every 30 minutes, on the half-hour. Please inquire at the front desk for details.
GETTING TO NIH
We strongly encourage you to take METRO to the Natcher Conference Center, particularly in light of increased security measures recently instituted at NIH to ensure the safety of NIH employees and property. The Natcher Conference Center is a five-minute walk from the Medical Center station on METRO's Red Line. The Natcher Building is located on Center Drive directly behind the Medical Center stop.
NIH Campus Map - Washington Metrorail Map
If you must drive, take the Wisconsin Avenue exit from the Capital Beltway (I-495) and travel south on Wisconsin Avenue toward Bethesda. Drive approximately 1.5 miles on Wisconsin Avenue, then enter the NIH campus by turning right onto South Drive. At the bottom of the hill, turn left onto Center Drive. The Natcher Building is at 45 Center Drive and is located across from the Library of Medicine.
Please note that all visitor vehicles, including taxicabs, hotel and airport shuttles, delivery trucks and vans will be inspected before being allowed on campus. Visitors will be asked to show a photo ID and state the purpose of their visit. Be sure to allow extra time for this vehicle inspection procedure.
An alternative to driving onto the NIH campus is to drive to Bethesda and park in a public lot. From Bethesda you can either take the METRO (stop is located at East West Highway and Wisconsin Avenue) to the Medical Center stop or walk up Wisconsin Avenue to Center Drive (about a 10-15 minute walk). You may also drive and park at other METRO Stops on the Red Line that have public parking and take the Metro to the Medical Center station. Convenient stops include Rockville, White Flint, and Grovesnor.
Participants are responsible for their own travel expenses; however, ESI Travel is available to assist you in making your travel arrangements for this meeting if you wish. Please be aware ESI Travel charges a $45 service fee with all ticket reservations. If you wish to use this service, please contact our travel agent, Bridget Hanafin, by e-mail at firstname.lastname@example.org.
Please have the following information available when you call or email:
- Event name: ORWH Symposium
- Your arrival and departure dates and departure city
- Your seating preference (aisle, window) and preferred time frame for traveling
- Your email address and/or fax number
- Payment information (major credit card)
If you are planning to travel by air, remember that heightened security has been implemented at all airports. Please be prepared to furnish e-ticket itineraries and receipts, along with government-issued photo identification, upon check-in. Travelers are advised to arrive at the airport at least two hours prior to their scheduled departure to ensure ample time to clear security. Also, please keep in mind that check-in procedures and policies vary according to each airport and airline. Upon arrival at the airport, we suggest that you ask airline personnel whether you are permitted to check in at the gate, as opposed to the main ticket
Online registration for this meeting is now open. Registration is open to the public and there is no fee. To register for the meeting, please click on the link below
If you encounter any problems with the registration page, please contact us.
| || |
Presented by the Office of Research on Women's Health, Office of the Director, National Institutes of Health; the Pediatric and Reproductive Endocrinology Branch, the National Institute of Child Health and Human Development, National Institutes of Health; the Department of Endocrinology, United States Naval Medical Center, Department of Defense; and the Pituitary Network Association.
STATEMENT BY TOMMY G. THOMPSON, Secretary of Health and Human Services
Urging Americans To Get Influenza Vaccine
A flu vaccination will protect the health of millions of Americans this flu season. That's why we have worked with manufacturers to ensure that there is more vaccine available in the United States this year than ever before.
We are urging people to visit a health professional and get vaccinated to protect themselves and their loved ones from the flu. Among those we recommend get vaccinated are people 50 years and older, women who will be pregnant during the flu season, and all children six to 23 months of age.
A full list of people who should get vaccinated is available at http://www.cdc.gov/flu/
Date: October 5, 2004
For Release: Immediately
Contact: HHS Press Office
STATEMENT FROM THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Regarding Chiron Flu Vaccine
Clearly, the loss of the Chiron flu vaccine poses a serious challenge to our
vaccine supply for the upcoming flu season. Chiron was to produce between
46-48 million doses of influenza vaccine for the United States. The
Department has begun pursuing contingencies for this loss of supply.
We currently anticipate having approximately 54 million doses of influenza
vaccine from Aventis and about another 1-2 million doses of FluMist nasal
spray. HHS had planned for a vaccine supply of about 100 million doses this
season, after a demand of about 87 million doses last flu season.
Our immediate focus will be on making sure that the supply we do have
reaches those who are most vulnerable. The Centers for Disease Control and
Prevention is convening its Advisory Committee on Immunization Practices to
prioritize its recommendations on who should get the flu vaccine for this
season based on the new vaccine supply information.
We will need the help of the public, the public health community and the
medical community to make sure that the vaccine goes to those who truly need
We are in the process of learning more detailed information about why the UK
regulatory authority suspended Chiron's license for three months and whether
anything can be done to address the issues involved. The Department of
Health and Human Services, including its Food and Drug Administration,
Centers for Disease Control and Prevention, and National Institutes for
Health, are working with their counterparts in the British government as
well as Chiron regarding this matter.
The Department also has begun exploring whether more flu vaccine can be
manufactured for this flu season. This includes working with Aventis on its
ability to provide more vaccine. At this point, however, it is not known
whether it's possible to get more vaccine.
HHS and its agencies will make more information available regarding the
influenza vaccine supply as it becomes available.
Note: All HHS press releases, fact sheets and other press materials are
available at http://www.hhs.gov/news.
Some Questions and Answers About Flu
.c The Associated Press
ATLANTA (AP) - Health officials say this year's flu outbreak, which has spread faster and earlier than usual, appears to be the worst in at least three years. Here are answers to some common flu season questions:
Q: What's the difference between a cold and flu?
A: Colds usually begin slowly and last only two to seven days, although it can be two weeks. They start with a scratchy, sore throat, followed by sneezing and a runny nose. You may get a mild cough later. Infants and young children can sometimes run temperatures up to 102 F. with a cold.
Flu often begins with a sudden headache and dry cough, possibly a runny nose and sore throat; also achy muscles and extreme fatigue. You may run a fever up to 104. Most people feel better in a couple of days, but the tiredness and cough can last for two weeks or longer. Flu can cause severe illness and life-threatening complications in some people.
Children may have symptoms - nausea, vomiting or diarrhea - that are not common for adults.
Flu can be confirmed with a test if given within two to three days after symptoms begin, but getting it isn't always practical.
Q: What flu symptoms are dangerous?
A: A combination of symptoms - sustained fever and chills, chest pain that gets worse when taking a deep breath and sputum that's a yellow color - can indicate pneumonia and a doctor should be consulted.
Q: Can I get the flu even though I got a flu shot this year?
A: Yes, although it often lessens the severity of the virus and can prevent deadly complications. Typically, the flu shot protects between 70 percent and 90 percent of healthy people under age 65. The elderly are more susceptible.
The power of the flu shot also depends on how well it matches the flu virus in circulation. The current Fujian flu strain that is affecting most people is not the strain in this year's flu shot. But disease experts say it is a close enough match that considerable protection should be provided.
Q: What are complications from the flu?
A: They include bacterial pneumonia, dehydration and worsening of chronic medical conditions such as congestive heart failure, asthma or diabetes. Seniors and those with chronic medical conditions are at highest risk.
Q: How is flu spread?
A: It spreads when an infected person coughs, sneezes or talks and the virus is sent into the air.
Q: How soon can I get sick from the flu?
A: It takes one to four days - on average two days - for a person exposed to the flu virus to develop symptoms.
Q: How do I protect myself?
A: The best way for individuals, particularly those at high risk for its serious complications, is to get a flu shot. It is particularly recommended for the elderly and children 6 months to 23 months.
Q: How many people get sick or die from the flu?
A: It's estimated 10 percent to 20 percent of U.S. residents get the flu and 114,000 are hospitalized each season for flu-related complications. Typically, it kills about 36,000 people in the United States each year, but experts say this year could be worse.
Source: Centers for Disease Control and Prevention.
On the Net: http://www.cdc.gov/flu/about/qa/
CDC information: http://www.cdc.gov/ncidod/diseases/flu/facts.htm
Merck Pulls Arthritis Drug from Market
By Ransdell Pierson
NEW YORK (Reuters) - Merck & Co Inc. on Thursday pulled its arthritis drug Vioxx off the market because it increases the risk of heart attack and stroke, a move that sent the company's shares plunging, erasing $25 billion of its market value.
Vioxx, used by two million people around the world, accounts for 10 percent of Merck's annual sales.
The withdrawal of the drug casts a cloud over an entire class of widely used arthritis and pain drugs known as COX-2 inhibitors. "This has implications for all members of this class," said Dr. Garret FitzGerald, chairman of the Department of Pharmacology at the University of Pennsylvania.
Merck said that in a colon cancer trial, patients who took Vioxx for three years faced twice the risk of cardiovascular events, such as heart attack and stroke, as patients taking a placebo.
"Patients who are currently taking Vioxx should contact their health care providers to discuss discontinuing use of Vioxx and possible alternative treatments," it said.
Concerns over the drug's side effects have been building in recent years after several studies showed risks attached to it. Other drugs in the same class, including Pfizer Inc.'s Celebrex and Bextra and Novartis AG's Prexige, have so far not shown the same dangers.
However, the U.S. Food and Drug Administration (news - web sites) said it would closely watch other such drugs.
Worldwide sales of Vioxx totaled $2.55 billion last year. Since its introduction in 1999, 84 million people have used the medication. In the United States alone, 91 million Vioxx prescriptions have been written. The drug is sold in some countries under the name Ceoxx.
"This is a very significant negative for Merck. Not only is this a nearly $3 billion drug, but it calls into question the future of one the key drugs in its pipeline, Arcoxia," said Scott Henry, an analyst at Oppenheimer & Co.
Arcoxia, which is similar to Vioxx, is sold outside the United States but has not yet been approved by the FDA (news - web sites) because of concerns about heart and stroke risk. Some analysts had expected the agency to rule on Arcoxia by late October.
Merck is already struggling with slowing earnings growth and faces the loss of patent protection for its biggest-selling drug, cholesterol fighter Zocor, in 2006.
Despite the setback, Merck Chairman and Chief Executive Raymond Gilmartin said he had no intention of resigning.
Merck is already gearing up for lawsuits over Vioxx. "We have substantial defenses in these cases and will defend them vigorously," said Kenneth Frazier, Merck's general counsel.
Merck shares fell 25 percent on the New York Stock Exchange (news - web sites). Shares of Pfizer, which sells two rival arthritis drugs, edged higher.
Vioxx sales have been flat in recent years amid safety concerns. Clinical trial data have shown the drug increased the incidence of blood clots tied to strokes and heart attacks.
A recent study by the U.S. Food and Drug Administration suggested patients taking Vioxx faced a 50 percent greater risk of heart attack and sudden cardiac death than those taking Celebrex.
Sales of the Pfizer drugs Celebrex and Bextra have steadily grown as doctors have turned to those medications, which have not been linked to heart attack and stroke.
The colon cancer trial was designed to evaluate the effectiveness of the standard 25-milligram Vioxx dose in preventing recurrence of colon polyps. Such polyps sometimes become cancerous.
Vioxx was used in the trial because some researchers theorize that inflammation, present in arthritis, may be linked to colon cancer.
Merck said the heart attacks and strokes were not spotted during the first 18 months of the trial but became apparent later.
"Given the availability of alternative therapies, and the questions raised by the data, we concluded that a voluntary withdrawal (of Vioxx) is the responsible course to take," Merck chief Gilmartin said.
Merck said it expects the cost associated with the recall to reduce earnings by 50 cents to 60 cents per share in the second half of the year, and will give more financial details on Oct. 21.
Merck said it planned to cut costs and said it remains comfortable with its earnings forecast for full-year 2004 of $3.11 to $3.17 per share.
Vioxx and the two Pfizer arthritis drugs are designed to block inflammation and pain as effectively as standard nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, while causing far fewer ulcers and gastrointestinal problems than the older treatments.
The newer medicines block a protein called COX-2 that has been linked to inflammation.
Merck said it would continue to market Arcoxia, which is sold in 47 countries. (Additional reporting by Toni Clarke and Edward Tobin)
Your patients may qualify for research
studies in the Neuroendocrine Clinical Center, Massachusetts General
Hospital, Boston, MA 02114. We are currently accepting the following
categories of patients for screening to determine study eligibility.
Depending on the study, subjects may receive free testing, medication
preoperative medical treatments
acromegaly requiring medical therapy
different medical therapies
history of cured acromegaly and current hypopituitarism
GH effects in patients with history of cured acromegaly and GH
Dr. Anne Klibanski
hypopituitarism (panhypopituitary or partial hypopituitarism)
||Dr. Beverly M.K.
Dr. Karen K. Miller
||Dr. Karen K.
Dr. Anne Klibanski
with anorexia nervosa
density and the effects of estrogen replacement
||Dr. Anne Klibanski
Dr. Madhu Misra
hypopituitarism, ages 18-50
replacement therapy study
||Dr. Karen K.
|HIV positive women
with weight loss or fat redistribution
Evaluation of bone loss
Evaluation of cardiovascular risk markers
|HIV positive men
and women with fat redistribution
treatments to redistribute fat
Determination of growth hormone levels and efficacy of GH
Novel lipid lowering therapy
Dr. Colleen Hadigan
Dr. Polyxeni Koutkia
Dr. Roberto Salvatori at Johns Hopkins has received a large grant from NIH to study the
consequences of lack of growth hormone and it's affects on heart function, bone density, muscle strength, and fat metabolism. It is a wonderful study but he has run into a problem with a delay in
receiving the funding. It apparently had to go through the Brazilian Gov. which is where the study will take place in a population of dwarfs that genetically have no growth hormone (a perfect study sample).
Receipt of the funds may be delayed anywhere from three to six months.
The study was scheduled to begin July 1 and an Endocrinology fellow, Dr. Danilo Fintini from Italy, is hired to do the research and begin July 12th, however there are no funds available yet to pay him. NIH grants require that the work be completed within a framework of time. To delay the project may cause a loss of the grant.
Any donation is tax deductible and greatly appreciated. $11,210 will be needed for the first three months and then another $11,210 for the next three months. This research when completed will help patients that are hypopituitary be treated with greater knowledge of the problem and insights in to how to help them recover strength, normal heart function and fat metabolism.
For more information about this study and Dr. Salvatori, in Word format:
please click here to download.
Thank you for your consideration in this matter. Please do not
hesitate to ask for more verification or information about the project. I look
forward to hearing from you soon.
We welcome your articles, letters to the editor, bios and
Cushing's information. Submit a Story or Article to
either the snailmail CUSH Newsletter or to an upcoming email
|To add or
edit your bio,
please click here »
Anne had a Left Adrenalectomy at St. Mike's Hosp in Toronto on May 25/04
Barrie, ON Canada
Roxanne had pituitary surgery September 17, 2003 followed by
Gamma Knife and is facing possibly more radiation treatment or surgery
Los Alamos, NM
Sharon will be having pituitary surgery on August 11th or Aug. 13th with Dr. Ian McCutcheon, neurosurgeon at the Brain and Spine Center of M.D. Anderson Cancer Center in Houston, TX
• If you've been diagnosed with Cushing's, please
participate in the
Cushing's Register »
The information you provide will be used to create a register
and will be shared with the medical world. It would not be used
for other purposes without your expressed permission. Note:
This information will not be sold or shared with other
Lynne Clemens, Secretary of
CUSH Org is be the
person responsible for the creation of this register. If you
have any questions you may contact her at
do not have to be a member of CUSH to fill out this
questionnaire, as long as you are a Cushing’s patient. We do not
believe that the world has an accurate accounting of Cushing’s
patients. The only way to authenticate accuracy is with actual
numbers. Your help will be appreciated. Thank you."